Literature DB >> 25787052

Spinal cord atrophy in multiple sclerosis and relationship with disability across clinical phenotypes.

Evanthia Bernitsas1, Fen Bao2, Navid Seraji-Bozorgzad3, Jessica Chorostecki3, Carla Santiago3, Alexandros Tselis1, Christina Caon1, Imad Zak4, Scott Millis5, Omar Khan6.   

Abstract

BACKGROUND: Several studies have shown a relationship between spinal cord atrophy and clinical disability in patients with multiple sclerosis (MS).
OBJECTIVES: We examined the correlation between cervical cord cross-sectional area at the C2 vertebral level (CSA-C2) and the expanded disability status scale (EDSS) in patients with relapsing-remitting and progressive forms of MS. The latter included both secondary and primary progressive MS patients.
METHODS: A total of 150 patients with MS were recruited from the Wayne State University MS clinic. Ninety-three had relapsing-remitting MS and 57 patients had progressive MS. MRI scan of the cervical cord was obtained for each patient. Correlation studies and multivariate regression analysis was performed, blinded to clinical status.
RESULTS: The mean age was 41.3 year old, 64.6% were women, mean disease duration was 11.2 years, CSA-C2 was 80.2mm(2) and mean EDSS was 3.8. There was significant correlation between CSA-C2 and EDSS (r -0.75, p<0.0001). Sub-group analysis showed CSA-C2 was 68.6mm(2) and 87.3mm(2) in the progressive and relapsing-remitting groups, respectively (p<0.0001). Multivariable regression showed that CSA-C2 was a significant predictor of disability independent of disease duration, and phenotype.
CONCLUSIONS: Our study demonstrates that CSA-C2 has a strong correlation with clinical disability in both RRMS and progressive MS. Greater spinal cord atrophy was seen in patients with progressive than relapsing-remitting MS. CSA-C2, disease duration, and phenotype are independent predictors of disability.
Copyright © 2014. Published by Elsevier B.V.

Entities:  

Keywords:  Disability; Disease progression; Magnetic resonance imaging (MRI); Multiple sclerosis; Spinal cord atrophy

Mesh:

Year:  2014        PMID: 25787052     DOI: 10.1016/j.msard.2014.11.002

Source DB:  PubMed          Journal:  Mult Scler Relat Disord        ISSN: 2211-0348            Impact factor:   4.339


  6 in total

Review 1.  The Role of Advanced Magnetic Resonance Imaging Techniques in Multiple Sclerosis Clinical Trials.

Authors:  Kedar R Mahajan; Daniel Ontaneda
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

2.  Is Time to Reach EDSS 6.0 Faster in Patients with Late-Onset versus Young-Onset Multiple Sclerosis?

Authors:  Raed Alroughani; Saeed Akhtar; Samar Ahmed; Raed Behbehani; Jasem Al-Hashel
Journal:  PLoS One       Date:  2016-11-01       Impact factor: 3.240

Review 3.  The Role of T1-Weighted Derived Measures of Neurodegeneration for Assessing Disability Progression in Multiple Sclerosis.

Authors:  Maria A Rocca; Giancarlo Comi; Massimo Filippi
Journal:  Front Neurol       Date:  2017-09-04       Impact factor: 4.003

Review 4.  Approved and Emerging Disease Modifying Therapies on Neurodegeneration in Multiple Sclerosis.

Authors:  Madeline Bross; Melody Hackett; Evanthia Bernitsas
Journal:  Int J Mol Sci       Date:  2020-06-17       Impact factor: 5.923

5.  Cervical and thoracic cord atrophy in multiple sclerosis phenotypes: Quantification and correlation with clinical disability.

Authors:  Yair Mina; Shila Azodi; Tsemacha Dubuche; Frances Andrada; Ikesinachi Osuorah; Joan Ohayon; Irene Cortese; Tianxia Wu; Kory R Johnson; Daniel S Reich; Govind Nair; Steven Jacobson
Journal:  Neuroimage Clin       Date:  2021-04-28       Impact factor: 4.881

6.  Quantitative measures of walking and strength provide insight into brain corticospinal tract pathology in multiple sclerosis.

Authors:  Nora E Fritz; Jennifer Keller; Peter A Calabresi; Kathleen M Zackowski
Journal:  Neuroimage Clin       Date:  2017-02-20       Impact factor: 4.881

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.